Taigen Biopharmaceuticals Holdings Ltd (4157) — Cash Flow Quality Index
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Cash Flow Quality Index of 0.23x as of December 2025. Operating cash flow of NT$46.51 Million is below net income of NT$204.72 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can Taigen Biopharmaceuticals Holdings Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Taigen Biopharmaceuticals Holdings Ltd Cash Flow Quality Index (2011–2025)
Historical Cash Flow Quality Index for Taigen Biopharmaceuticals Holdings Ltd across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 4157 cash flow conversion.
Annual Cash Flow Quality Index for Taigen Biopharmaceuticals Holdings Ltd (2011–2025)
Year-by-year earnings quality comparison for Taigen Biopharmaceuticals Holdings Ltd.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.46x | NT$20.93 Million | NT$45.18 Million | ▲ +205.4% |
| 2023 | 0.15x | NT$20.74 Million | NT$136.73 Million | ▼ -78.9% |
| 2021 | 0.72x | NT$629.07 Million | NT$875.99 Million | ▲ +300.8% |
| 2017 | -0.36x | NT$-266.93 Million | NT$746.38 Million | ▲ +96.0% |
| 2011 | -8.85x | NT$-379.23 Million | NT$42.84 Million | — |